Phenethyl isothiocyanate suppresses receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis by blocking activation of ERK1/2 and p38 MAPK in RAW264.7 macrophages

BioFactors

Volumn 30, Issue 1, 2007, Pages 1-11

  Murakami, Akira ^a   Song, Meiyu ^a   Ohigashi, Hajime ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b FUKUI PREFECTURAL UNIVERSITY   (Japan)

Author keywords

Isothiocyanate; MAP kinase; Osteoclastogenesis; RANKL; RAW264.7 cells

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PHENETHYL ISOTHIOCYANATE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL LINEAGE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HEMATOPOIETIC CELL; LIGAND BINDING; MACROPHAGE; MACROPHAGE ACTIVATION; MOLECULAR MECHANICS; MONOCYTE; MOUSE; NFATC1 GENE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHYTOCHEMISTRY; PRIORITY JOURNAL; REGULATOR GENE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TURNIP;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; ENZYME ACTIVATION; ISOTHIOCYANATES; MACROPHAGES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RANK LIGAND;

MURINAE;

EID: 38049067227     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520300101     Document Type: Article

References (31)

1. A.C. Bharti, Y. Takada and B.B. Aggarwal, Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis, J Immunol 172(10), 5940-5947.
2. F. Bianchini and H. Vainio, Isothiocyanates in cancer prevention, Drug Metab Rev 36 (2004), 655-667.
3. J.D. Brooks, V.G. Paton and G. Vidanes, Potent induction of phase 2 enzymes in human prostate cells by sulforaphane, Cancer Epidemiol Biomarkers Prev 10 (2001), 949-954.
4. L. Calleros, M. Lasa, M.J. Toro and A. Chiloeches, Low cell cholesterol levels increase NFkappaB activity through a p38 MAPK-dependent mechanism, Cell Signal 18 (2006), 2292-2301.
5. B.C. Chen and W.W. Lin, PKC- and ERK-dependent activation of I kappa B kinase by lipopolysaccharide in macrophages: enhancement by P2Y receptor-mediated CaMK activation, Br J Pharmacol 134 (2001), 1055-1065.
6. S.Y. Cho, S.J. Park, M.J. Kwon, T.S. Jeong, S.H. Bok, W.Y. Choi, W.I. Jeong, S.Y. Ryu, S.H. Do, C.S. Lee, J.C. Song and K.S. Jeong, Quercetin suppresses proinflammatory cytokines production through MAP kinases and NF-kappaB pathway in lipopolysaccharide-stimulated macrophage, Mol Cell Biochem 243 (2003), 153-160.
7. L.A. Ehrlich and G.D. Roodman, The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma, Immunol Rev 208 (2005), 252-266.
8. N. Giuliani, S. Colla and V. Rizzoli, New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL), Exp Hematol 32 (2004), 685-691.
9. L.C. Hofbauer and M. Schoppet, Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases, JAMA 292 (2004), 490-495.
10. B. Holst and G. Williamson, A critical review of the bioavailability of glucosinolates and related compounds, Nat Prod Rep 21 (2004), 425-447.
11. H. Hotokezaka, E. Sakai, K. Kanaoka, K. Saito, K. Matsuo, H. Kitaura, N. Yoshida and K. Nakayama, U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells, J Biol Chem 277(49), 47366-47372.
12. H. Huang, E.J. Chang, J. Ry, Z.H. Lee, Y. Lee and H.H. Kim, Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway, Biochem Biophys Res Commun 351 (2006), 99-105.
13. R. Hu, B.R. Kim, C. Chen, V. Hebbar and A.N. Kong, The roles of JNK and apoptotic signaling pathways in PEITC-mediated responses in human HT-29 colon adenocarcinoma cells, Carcinogenesis 24 (2003), 1361-1367.
14. J. Hu, H. Nakano, H. Sakurai and N.H. Colburn, Insufficient p65 phosphorylation at S536 specifically contributes to the lack of NF-kappaB activation and transformation in resistant JB6 cells, Carcinogenesis 25 (2004), 1991-2003.
15. Y. Ikeda, A. Murakami and H. Ohigashi, Ursolic acid promotes the release of macrophage migration inhibitory factor via ERK2 activation in resting mouse macrophages, Biochem Pharmacol 70 (2005), 1497-1505.
16. J. Jakubikova, J. Sedlak, J. Bacon, A. Goldson and Y. Bao, Effects of MEK1 and PI3K inhibitors on allyl-, benzyl- and phenylethyl-isothiocyanate- induced G2/M arrest and cell death in Caco-2 cells, Int J Oncol 27 (2005), 1449-1458.
17. J.H. Je, J.Y. Lee, K.J. Jung, B. Sung, E.K. Go, B.P. Yu and H.Y. Chung, NF-kappaB activation mechanism of 4-hydroxyhexenal via NIK/IKK and p38 MAPK pathway, FEBS Lett 566 (2004), 183-189.
18. S. Kanno, S. Hirano and F. Kayama, Effects of the phytoestrogen coumestrol on RANK-ligand-induced differentiation of osteoclasts, Toxicology 203 (2004), 211-220.
19. S.J. Kim, S.Y. Kang, H.H. Shin and H.S. Choi, Sulforaphane inhibits osteoclastogenesis by inhibiting nuclear factor-kappaB, Mol Cells 20 (2005), 364-370.
20. S.V. Kyosseva, Mitogen-activated protein kinase signaling, Int Rev Neurobiol 59 (2004), 201-220.
21. J.S. Lee and Y.J. Surh, Nrf2 as a novel molecular target for chemoprevention, Cancer Lett 224 (2005), 171-184.
22. V.W. Lui, A.L. Wentzel, D. Xiao, K.L. Lew, S.V. Singh and J.R. Grandis, Requirement of a carbon spacer in benzyl isothiocyanate-mediated cytotoxicity and MAPK activation in head and neck squamous cell carcinoma, Carcinogenesis 24 (2003), 1705-1712.
23. M. Matsumoto, T. Sudo, T. Saito, H. Osada and M. Tsujimoto, Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL), J Biol Chem 275 (2000), 31155-31161.
24. N. Miyoshi, K. Uchida, T. Osawa and Y. Nakamura, A link between benzyl isothiocyanate-induced cell cycle arrest and apoptosis: involvement of mitogen-activated protein kinases in the Bcl-2 phosphorylation, Cancer Res 64 (2004), 2134-2142.
25. Y. Nakamura and N. Miyoshi, Cell death induction by isothiocyanates and their underlying molecular mechanisms, Biofactors 26 (2006), 123-134.
26. M.M. Rahman, A. Bhattacharya and G. Fernandes, Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling, J Lipid Res 47 (2006), 1739-1748.
27. E. Romas, M.T. Gillespie and T.J. Martin, Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis, Bone 30 (2002), 340-346.
28. S.A. Schwartz, A. Hernandez and B. Mark Evers, The role of NF-kappaB/IkappaB proteins in cancer: implications for novel treatment strategies, Surg Oncol 8 (1999), 143-153.
29. D. Sladowski, S.J. Steer, R.H. Clothier and M. Ball, An improved MTT assay, J Immunol Methods 157 (1993), 203-207.
30. N. Udagawa, S. Kotake, N. Kamatani, N. Takahashi and T. Suda, The molecular mechanism of osteoclastogenesis in rheumatoid arthritis, Arthritis Res 4 (2002), 281-289.
31. Y. Zhang and P. Talalay, Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms, Cancer Res 54 (1994), 1976s-1981s.